Navigation Links
Pharmos Corporation Reports 2009 First Quarter Results
Date:5/12/2009

ISELIN, N.J., May 12 /PRNewswire-FirstCall/ -- Pharmos Corporation (Pink Sheets: PARS) today reported results for the first quarter ended March 31, 2009. The Company recorded a net loss of $3.7 million, or $0.14 per share, for the first quarter 2009 compared to a net loss of $3.6 million, or $0.14 per share, in the first quarter 2008. Cash and short-term investments totaled $2.9 million at March 31, 2009.

The slight increase in net loss for the first quarter 2009 vs. first quarter 2008 is due to in process research and development costs which were related to a milestone payment of $1.2 million to the former Vela shareholders. These expenses were offset by a 28% decrease in research & development expenses and a 58% decrease in general and administrative expenses.

Research & development expenses decreased by $763,814 or 28% from $2,778,234 in 2008 to $2,014,420 in 2009, related to the Company's primary focus of cash resources on the Dextofisopam Phase 2b trial and the downsizing and curtailment of general research and development programs. The decline reflects decreases in virtually every research and development expense category. The primary reductions include a $285,000 reduction in payroll, a $157,000 reduction in consultant and professional fees, a $195,000 reduction in clinical studies and $127,000 reduction in various other areas. The decline in expenses primarily reflects the closing of the Rehovot facility.

In the quarter ended March 31, 2009, the Company advanced a Phase IIb trial of its lead compound, dextofisopam, in female IBS patients. The Phase IIb trial was fully enrolled on April 9, 2009 at 324 patients. Costs of $1,884,000 were incurred during the quarter in connection with the trial, comprising CRO-related activities and patient recruitment costs. All patients in the trial are expected to complete treatment by mid 2009 and top line clinical data is expected in early September 2009. A
'/>"/>

SOURCE Pharmos Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Pharmos Completes Private Placement - Raises $1.8 Million
2. Pharmos Corporation Announces Receipt of Nasdaq Delisting Determination
3. Pharmos Corporation Announces Modification to Dextofisopam Trial Size, Objectives Can Still Be Achieved
4. Pharmos Corporation Announces Receipt of Nasdaq Noncompliance Letter
5. Pharmos Corporation Reports 2008 Third Quarter Results
6. Pharmos Corporation Reports 2007 Fourth Quarter and Year-end Results
7. Pharmos Restructures Operations in Israel
8. Volcano Corporation Presentation at JMP Conference to be Webcast
9. Medical Care Corporation Enables Early Detection of Memory Loss Due to Alzheimers Disease
10. Quigley Corporation Receives Support from Leading Independent Proxy Advisory Firms; RiskMetrics and Glass Lewis Reject Dissident Stockholder Ted Karkus, Citing Failure to Provide Detailed Business Plan
11. Former Executive Director of the World Bank and CEO of OMERS Nominated as Directors for Biovail Corporations Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... (PRWEB) July 14, 2014 According to the ... is a helpful guide that features a series of new ... in its review that this book can help readers understand ... of high blood pressure, and effective methods to control ... are reviewed now by Vkool, was penned by Ken Burge, ...
(Date:7/14/2014)... According to the Boost Your Bust book review recently ... want to learn how to increase the size of their breasts ... chapters including:, , Chapter 1 – What Are ... 2 – How Natural Breast Enlargement Works , Chapter ... Chapter 4 – The Groundwork , Chapter ...
(Date:7/14/2014)... July 14, 2014 "Medical devices, tests, ... of us. The Tri-Valley is a star when it ... in the region are working on amazing products and ... face of medicine," according to Dale Kaye CEO of ... showcase some of the brilliant minds and businesses that ...
(Date:7/14/2014)... July 14, 2014 Reha Technology ... a compact, portable and full-featured upper extremity robotic ... use of interactive games and challenges in a ... Occupational Therapy , Armotion combines a ... order to maximize the therapy effect for patients ...
(Date:7/14/2014)... COPENHAGEN Participation in activities that promote mental ... may help protect against the development of Alzheimer,s ... new research reported today at the Alzheimer,s Association ... , Research reported at AAIC 2014 also showed ... post-traumatic stress disorder (PTSD) may increase dementia ...
Breaking Medicine News(10 mins):Health News:Blood Pressure Solution Book Review Exposes Ken Burge's Hypertension Treatment Guide – Vkool.com 2Health News:Blood Pressure Solution Book Review Exposes Ken Burge's Hypertension Treatment Guide – Vkool.com 3Health News:Boost Your Bust Book Review Exposes Jenny Bolton's Breast Enhancement Guide – Vkool.com 2Health News:Boost Your Bust Book Review Exposes Jenny Bolton's Breast Enhancement Guide – Vkool.com 3Health News:Believing in the Possible – Innovation Tri-Valley’s Sixth Innovation Forum Examines the Tri-Valley’s Wealth of Innovators 2Health News:Believing in the Possible – Innovation Tri-Valley’s Sixth Innovation Forum Examines the Tri-Valley’s Wealth of Innovators 3Health News:Believing in the Possible – Innovation Tri-Valley’s Sixth Innovation Forum Examines the Tri-Valley’s Wealth of Innovators 4Health News:Reha Technology Launches the Armotion™, a Device for the Rehabilitation of the Upper Extremity 2Health News:Potential Alzheimer's disease risk factor and risk reduction strategies become clearer 2Health News:Potential Alzheimer's disease risk factor and risk reduction strategies become clearer 3Health News:Potential Alzheimer's disease risk factor and risk reduction strategies become clearer 4Health News:Potential Alzheimer's disease risk factor and risk reduction strategies become clearer 5Health News:Potential Alzheimer's disease risk factor and risk reduction strategies become clearer 6
... Animal Dermatology Clinic,announces the grand opening of their ... in Pasadena, CA. The 3,700 square foot facility ... room, where laser,surgeries, allergy testing, biopsies, and other ... on-site, in a quiet and stress-free,environment. There is ...
... 31 Rib-X Pharmaceuticals, Inc.,("Rib-X" or the "Company"), ... commercialization of novel antibiotics for the,treatment of antibiotic-resistant ... PhD, was honored last night by The,Connecticut Women,s ... & Induction,Ceremony. As part of this year,s event, ...
... International has,named John T. Kelly, M.D., Ph.D. as Chief ... to improve the health and,wellness of the users of ... "Our mission is to promote healthier lifestyles and ... "Dr. Kelly will,play a key role in our strategy. ...
... Stylish and Sophisticated, Life is Full of,Possibilities and ... Loss., PISCATAWAY, N.J., Oct. 31 Personalizing,solutions for ... Siemens Hearing,Instruments, Inc., a leading manufacturer of hearing ... announcing their new Life,hearing instruments at this year,s ...
... from strangers, expert says , , FRIDAY, Oct. 31 (HealthDay ... parents are wondering how they can help keep their ... of pediatric emergency services at Morgan Stanley Children,s Hospital ... make Halloween a happy and safe occasion for everyone. ...
... HOUSTON, Oct. 31 Cyberonics, Inc. (Nasdaq:,CYBX) ... Medicaid Services,(CMS) has published the 2009 CMS Outpatient ... Classification (APC) rate for VNS,Therapy. The final rule, ... at $12,545 for insertion of VNS Therapy generators ...
Cached Medicine News:Health News:Animal Dermatology Clinic Announces Today the Grand Opening of a State of the Art Veterinary Specialty Practice in Pasadena, California 2Health News:Rib-X CEO Susan Froshauer, PhD, Honored by The Connecticut Women's Hall of Fame 2Health News:Rib-X CEO Susan Froshauer, PhD, Honored by The Connecticut Women's Hall of Fame 3Health News:Lifeclinic Names Harvard Ph.D. as New Chief Medical Officer 2Health News:Siemens Introduces Life, an Open Fit Hearing Instrument That is Beautiful, Smart, and Discreet 2Health News:Siemens Introduces Life, an Open Fit Hearing Instrument That is Beautiful, Smart, and Discreet 3Health News:Siemens Introduces Life, an Open Fit Hearing Instrument That is Beautiful, Smart, and Discreet 4Health News:Family Halloween Safety Can Be Fiendishly Simple 2Health News:Cyberonics Provides Business Update Based on Final Ambulatory Payment Classification Rate Change Announcement by CMS 2Health News:Cyberonics Provides Business Update Based on Final Ambulatory Payment Classification Rate Change Announcement by CMS 3
(Date:7/11/2014)... July 11, 2014 Research and Markets ... and Chinese Medical X-ray Film Industry Report 2014" ... http://photos.prnewswire.com/prnh/20130307/600769 Global And Chinese Medical X-Ray ... study on the current state of the Global medical ... situation. The report provides a basic overview of ...
(Date:7/11/2014)... , July 11, 2014  Kindred Hospital ... to announce the opening of its new outpatient ... outpatient services to people with chronic, hard to ... which can lead to amputation, lower leg wounds ... have delayed closure, and traumatic injury wounds which ...
(Date:7/11/2014)... , July 11, 2014 According ... Research "Endoscopy Devices Market (Endoscopes, Endoscopic Operative Devices, and ... Trends and Forecast, 2013-2019" the global endoscopy devices market ... is expected to grow at a CAGR of 6.8% ... of USD 36.9 billion in 2019. Browse ...
Breaking Medicine Technology:Global and Chinese Medical X-ray Film Industry Report 2014 2Kindred Hospital Houston Northwest, With Wound Care Specialists, Opens Outpatient Wound Healing And Hyperbaric Center 2Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 2Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 4Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 5Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 6
... , , , ... SAN DIEGO, Sept. 18, 2009 Arena Pharmaceuticals, Inc. (Nasdaq: ... BLOSSOM (Behavioral modification and LOrcaserin Second Study for Obesity Management) trial. BLOSSOM ... for Overweight and Obesity Management) trial and completes the lorcaserin Phase 3 ...
... , NEWNAN, Ga., Sept. 16 CeloNova ... make two presentations at the Cardiovascular and Interventional Radiology Society ... excellent clinical results in treating liver cancer. Professor Orsi and ... Italy have developed a technique to cut off the blood ...
Cached Medicine Technology:Arena Pharmaceuticals Reports Positive, Highly Significant BLOSSOM Trial Results for Weight Management; NDA Submission on Track for December 2Arena Pharmaceuticals Reports Positive, Highly Significant BLOSSOM Trial Results for Weight Management; NDA Submission on Track for December 3Arena Pharmaceuticals Reports Positive, Highly Significant BLOSSOM Trial Results for Weight Management; NDA Submission on Track for December 4Arena Pharmaceuticals Reports Positive, Highly Significant BLOSSOM Trial Results for Weight Management; NDA Submission on Track for December 5Arena Pharmaceuticals Reports Positive, Highly Significant BLOSSOM Trial Results for Weight Management; NDA Submission on Track for December 6Arena Pharmaceuticals Reports Positive, Highly Significant BLOSSOM Trial Results for Weight Management; NDA Submission on Track for December 7Arena Pharmaceuticals Reports Positive, Highly Significant BLOSSOM Trial Results for Weight Management; NDA Submission on Track for December 8Arena Pharmaceuticals Reports Positive, Highly Significant BLOSSOM Trial Results for Weight Management; NDA Submission on Track for December 9Arena Pharmaceuticals Reports Positive, Highly Significant BLOSSOM Trial Results for Weight Management; NDA Submission on Track for December 10Arena Pharmaceuticals Reports Positive, Highly Significant BLOSSOM Trial Results for Weight Management; NDA Submission on Track for December 11Arena Pharmaceuticals Reports Positive, Highly Significant BLOSSOM Trial Results for Weight Management; NDA Submission on Track for December 12New Micro-Bland Embolization Technique with Embozene(TM) Microspheres to Be Presented at the International Medical Conference in Lisbon, Portugal 2
Stryker's 40-liter insufflator provides superior performance with unprecedented safety and reliability....
Bipolar forceps...
... visualize the presence of Human Papilloma Virus (HPV)., ... sample types: tissue, monolayer-based preparations, and conventional Pap. ... The Family 16 probe cocktail has an affinity ... 39, 51, 52, 56, 58, and 66. The ...
... Common primary human fungal pathogens ... spp., opportunistic fungal pathogens, including ... cerevisiae, Acremonium, Coccidioides immitis, Histoplasma ... and Pneumocystis carinii. The (1-3)--D-glucan ...
Medicine Products: